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Induction of glomerular inflammation by antibodies to Clq. I.E.M.
Coremans, J.A. Brujn, E. de Heer, E.A.M. van der Voort, F.C.
Breedveld, and M.R. Daha, Departments of Rheumatology, Pathology
and Nephrology, University Hospital, Leiden, The Netherlands. In
patients with systemic lupus erythematosus (SLE) autoantibodies to
Clq (CiqAb), a subcomponent of the complement system, have been
described. In a transversal study of 88 SLE patients a correlation has
been found between the presence of CiqAb and renal involvement.
This suggests that CiqAb may play a role in the pathogenesis of lupus
nephritis. In the present study we investigated whether human (hu) Clq
could be deposited along the glomerular capillary wall (GCW) in mice,
and secondly whether CiqAb could form immunecomplexes (ICx)
locally in situ. Groups of six male Balb/c mice were injected with 2 mg
hu Clq intraperitoneally. Clear deposits of hu Clq were found after 24
hours. Intraperitoneal injection of '251-hu Clq revealed that 1% of the
injected dose was present in the kidney at 24 hours which disappeared
gradually in time. Another group of nine mice was also injected with 2
mg of hu Clq intraperitoneally, followed 24 hours later by 5 mg of a
rabbit polyclonal anti-hu Clq intravenously. Mice were sacrificed six
hours, 24 hours, and seven days after injection of the Ab. Granular
depositions of hu Clq and rabbit IgG along the GCW were found at all
the different time points by immunofluorescence. By transmission
electronmicroscopy at day 7, immune deposits could be found in the slit
pores of the glomerular basement membrane. An increase of albumin
excretion was found at day 2 after injection of the rabbit anti-hu ClqAb.
These findings demonstrate that Clq is able to deposit in the GCW and
that ClqAb are potentially able to induce glomerular inflammation.
Isolation and functional expression of a cDNA for rat CHIP28 water
channel. P.M.T. Deen, J.A. Dempster, B. Wieringa, and C.H. van Os,
Departments of Physiology and Cell Biology, University of N(jmegen,
The Netherlands. High water permeability of proximal tubules and
erythrocytes is due to membrane proteins serving specifically as water
channels. The cDNA encoding the human red blood cell water channel
CHIP28 has recently been isolated. Expression of CHIP28 in Xenopus
oocytes proved that this protein is a water channel. Radiation inactiva-
tion studies revealed the same size for the water channel in proximal
tubules and in erythrocytes. We now show that a cDNA for CHIP28 can
be isolated from rat kidney, First, by means of PCR, a 600 bp product
coding for part of the human CHIP28 was obtained from a fetal liver
cDNA library. With this probe, a rat kidney cDNA library was screened
and with an additional reverse transcriptase PCR technique, a full-
length rat cDNA clone of 2.7 kb was isolated. The similarity with the
amino acid sequence of the human red blood cell CHIP28 is 93%. The
protein-encoding sequence is >80% identical. Subsequently, mRNA
was isolated from the rat renal outer cortex and the inner medulla. By
means of Northern blot hybridization, it was shown that CHIP28 is
well-expressed in both cortex and medulla. The level of CHIP28
expression was not different in diuresis and antidiuresis. Xenopus
oocytes microinjected with 10 ng in vitro transcribed rat CHIP28 RNA
exhibited increased osmotic water permeability (after 3 days Pf = 79
10 sms', N = 16, at 4°C compared to controls injected with water, Pf
= 0 0.5 ms', N = 10). In conclusion, the rat renal CHIP28 is 93%
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identical to human erythrocyte CHIP28 and Northern blot analysis
strongly suggests that water channel proteins in the proximal tubule and
the collecting duct are identical.
In vitro model of epithelial hyperplasia in murine autosomal recessive
polycystic kidney disease (ARPKD). J. Nauta, W.E. Sweeney, and E.D.
Avner, University of Washington and Children's Hospital, Department
of Pediatrics, Seattle, Washington, USA, and University of Rotterdami
Sophia Children's Hospital, Rotterdam, The Netherlands. Human
ARPKD is characterized by both renal and hepatobiliary lesions.
Epithelial hyperplasia is a hallmark of the lesions in both organs.
Studies have suggested a role for the EGF-EGF receptor in cystic renal
hyperplasia. We have recently demonstrated the presence of renal and
hepatobiliary hyperplasia in a new murine model of ARPKD, the BPK
mouse. To explore the cellular basis of abnormal epithelial growth in
ARPKD, we developed a culture system of biliary epithelial cells and
characterized the growth of BPK derived cultures following stimulation
with a variety of polypeptide growth factors. Common bile duct
explants from BPK and control mice (CON) were grown in serum free
basal medium (BM) with or without supplementation with FBS (10%),
IGF 1,11 (25 nglml), EGF (20 nglml), a/bFGF (12 nglml), KGF (12
ng/ml), HGF (20 ng/ml), TGFp (2.5 ng/ml). Cellular outgrowth was
characterized ultrastructurally and by immunocytochemistry. Mito-
genic activity was assessed by colony morphometrics and by six hour
3H Thymidine uptake of primary cultures at day 7. Cellular outgrowth
from bile duct explants formed tight, contact inhibited, homogenous
epithelial monolayers which expressed binding sites for anti-human
cytokeratin antibodies and for DBA. Colony growth curves did not
differ between BPK and CON in BM. The effects of EGF on colony
growth and 3H Thymidine uptake as percent over BM were for CON
l30%* and l3l%*, and for BPK 156%*x and 240%*(. Effects in CON
for FBS (l41%*, —), KGF (94%, 156%*) and TGFI3 (87%, 6l%*) were
similar in BPK. No significant effects were seen with IGF,, IGF2,
aFGF, bFGF and HGF (*P < 0.01 vs. BM, XJ < 0.01 vs. CON).
Coupled with previous findings in the kidney this EGF dependant in
vitro hyperplasia suggests a role for the EGF-EGF receptor system in
both renal and hepatobiliary hyperplasia in ARPKD. This culture
system offers new opportunities for further studies of the cellular
pathophysiology of ARPKD.
Glomerular hypertension In young fawn-hooded rats. J.L. Simons,
A.P. Provoost, S. Anderson, J.L. Troy, H.G. Rennke, DJ. Sandstrom,
and B.M. Brenner, Department of Pediatric Surgery, Erasmus Univer-
sity Rotterdam, The Netherlands, and Renal Division and Departments
of Medicine and Pathology, Brigham and Women's Hospital, The
Harvard Center for The Study of Kidney Diseases, Harvard Medical
School, Boston, Massachusetts, USA. Fawn-hooded (FH) rats sponta-
neously develop focal and segmental glomerular sclerosis (FGS), sys-
temic hypertension and proteinuria at a young age. Through selective
inbreeding two strains of FH rats were obtained, FHH and FHL, with
different susceptibilities to develop chronic renal failure. FHH rats have
higher values for systolic blood pressure and proteinuria and more rapid
development of FGS and chronic renal failure (CRF) than FHL rats. To
determine the role of glomerular hemodynamic (hypertension) and
structural (hypertrophy) factors in the development of FGS, we per-
formed micropuncture and morphological studies in FHH and FHL,
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before extensive damage was present. The results were compared with
those of a normotensive Wistar (WAG) control strain. Five groups,
each consisting of seven to eight rats, were studied. FHH, FHL, and
WAG were matched for age and were studied at 16 weeks. FHH, FHL
and WAG-old (WAG-O) strains were matched for body weight, the last
group studied at 22 weeks. WAG were also matched for body weight to
a young group of FHH rats (FHH-Y) and these were studied at eight
weeks. In comparison with WAG and WAG-O rats, FHH and FHH-Y
rats exhibited an increase in mean glomerular capillary hydraulic
pressure (WAG, 52 mm Hg; WAG-O, 47 2 mm Hg; FHH, 60 2
mm Hg; FHH-Y, 65 1 mm Hg), whereas values in FHL animals were
intermediate (FHL, 56 2 mm Hg). No significant differences in mean
glomerular volume were present between the various groups, mean
values being in the order of 1.4 to 1.6 10-6 .tm3. Mild FGS (about 5% of
the glomeruli) was present in FHH and FHH-Y rats, compared to about
1% for FHL and less than 0.5% for WAG and WAG-O. Thus, the
genetically determined sensitivity to develop proteinuria, FGS, and
CRF in the inbred strains of FH rats was associated with early evidence
of glomerular capillary hypertension. By contrast, glomerular hypertro-
phy was not a prerequisite for early glomerular injury.
Similar systemic and renal effects of angiotensin-Il (A-Il) receptor
antagonism and ACE inhibition (ACE1) in non-diabetic renal disease. Ron
T. Gansevoort, Dick de Zeeuw, and Paul E. de Jong, University
Hospital, Groningen, The Netherlands. ACEi causes specific renal
effects, such as a rise in ERPF, a fall in filtration fraction and a lowering
of proteinuna. The mechanism of this antiproteinuric effect is still
debated. Recent animal studies suggest that non-A-IL related actions of
ACEi, such as bradykinin accumulation, may play a role. A study
comparing the effects of ACEi to more specific intervention in the renin
angiotensin system (RAS) with the A-I! receptor antagonist MK-954
might resolve this question. We therefore investigated the effects of
MK-954 and enalapril in seven patients with non-diabetic proteinuria
> 2 g/day and hypertension (DBP  90mm Hg). The protocol consisted
of seven periods, each lasting one month, in which patients received
once daily placebo, 50 mg MK-954, 100 mg MK-954, placebo, 10 mg
enalapril, 20 mg enalapril and placebo, respectively. Patients used no
other medication and adhered to a 100 mmol sodium restricted diet. At
the end of each study period proteinuria, blood pressure and renal
function were determined:
MK-954
Baseline 50 mg 100 mg
Proteinuriag/day
MAP mm Hg
GFR mI/mm
ERPF mI/mm
FF %
5.9 1.7 4.3 1.8
113.2 2.6 99.6 2.5
74.9 5.9 73.6 5.1
335 15 371 22
22.4 1.4 20.0 1.2
3.9 1.7
95.2 3.1
69.5 4.0
376 15
18.5 0.8
Wash-out
Enalapril
Wash-out10 mg 20 mg
4.9 2.0
109.9 2.7
72.8 4.4
328 14
22.2 1.0
3.8 1.8 3.1 1.3
100.0 3.5 94.5 2.3
74.2 3.7 70.2 5.5
371 15 362 14
20.2 1.1 19.4 1.2
4.4 1.4
108.1 4.4
73.2 3.6
319 15
23.0 0.8
On both doses of MK-954 and enalapril proteinuria and MAP fell,
whereas ERPF increased, while GFR remained stable. The changes
were all significantly different from the respective baseline values. On
both drugs these changes seem to be dose-dependent, although a
time-dependent mechanism cannot be ruled out. The fall in proteinuria
was not significantly different for both drugs when compared to the
respective baseline values (43.5 8.7% on 100 mg MK-954 vs. 45.5
8.2% on 20mg enalapril). The same holds true for the fall in MAP (15.8
2.1% vs. 13.9 0.9%), the rise in ERPF (12.4 2.2% vs. 10.6
2.1%) and the fall in FF (16.0 3.5% vs. 12.9 2.9%). Conclusion: the
A-Il receptor antagonist MK-954 induces changes in blood pressure,
renal hemodynamics, and proteinuria similar to those induced by ACEi.
These data do not support the idea that the renal effects, specific for
ACEi, are mediated by other hormonal systems than the RAS.
Adenosine Al-receptor blockade with oral FK453 in essential hyper-
tensives increases Na excretion and lowers blood pressure, without an
effect on renal hemodynamics. Marjolun van Buren, Hem A. Koomans,
Herman f.M. van RUn, Jane Restorick, and Gary Acton, Department
of Nephrology and Hypertension, University Hospital Utrecht, The
Netherlands, and Fujisawa Pharmaceutical Company, Ltd., London,
United Kingdom. FK453 is a novel, highly selective adenosine A1-
receptor antagonist. We investigated the effects of FK453 on renal
hemodynamics and electrolyte handling, systemic blood pressure and
heart rate in eight patients with essential hypertension, on a 150 mmol
Na180 mmol K diet. FK453, 100 mg, was taken once daily for seven
days. Clearance studies under maximal water diuresis were carried out
on days I and 7. FK453 acutely increased sodium excretion on day 1
(from 200 37 to 662 89 smotImin in 2 hours) and, to a lesser extent,
on day 7 (from 157 28 to 401 66 mol/min). FK453 had no
consistent effect on renal filtration rate (C11), plasma flow (CPAH) and
filtration fraction. Urine flow increased and minimal urine osmolality
remained unaltered. Fractional distal delivery, estimated from the
maximal free water clearance, increased, while distal reabsorption
decreased. FK453 consistently increased the excretion of lithium,
phosphate, uric acid, magnesium and calcium, whereas potassium
excretion increased only on day 1. FK453 doubled plasma renin activity
on both day I and day 7, without any effect on plasma aldosterone.
c-AMP excretion showed a significant increase on both study days. The
natriuretic effect appeared short-lasting, and was followed by a tran-
sient compensatory Na retention on days 2 to 5, despite continued
FK453 treatment. Throughout the study, FK453 acutely lowered blood
pressure from 169/98 6/5 to 146/87 7/6 mm Hg, and increased heart
rate by about 10 4 beats/mm. These effects appeared to be short-
lasting, and blood pressure values attained baseline levels prior to each
next dose. We conclude that FK453 acutely increases Na excretion, by
an effect on both proximal and distal parts of the nephron, and lowers
blood pressure, but has no effect on renal haemodynamics. Its potential
as a hypotensive drug should be evaluated in further study.
Polymeric- and dimeric-IgA but not monomeric-IgA bind to rat renal
mesangial cells in vitro. M.E.A. van den Dobbelsteen, F.J. van der
Woude, W,E.M. Schroeijers, L.A. van Es, and M.R. Daha, Depart-
ment of Nephrology, University Hospital Leiden, The Netherlands.
The mesangium plays a crucial role in processes of inflammation in the
kidney. We have shown previously that IgG can bind to mesangial cells
(MC) via specific Fcy receptors. Since depositions of IgA are found in
the mesangium in patients with IgA nephropathy, we have now inves-
tigated whether IgA is able to bind to cultured rat mesangial cells in
vitro. As a source of IgA, a monomeric- (mIgA), dimeric- (di-IgA) and
polymeric IgA-a-DNP (pIgA) monoclonal antibody was used. Incuba-
tion of MC with m-, di- and pIgA, followed by FACS analysis revealed
binding of di- and pIgA and very little of mIgA. Additional experiments
with radiolabeled IgA of various sizes indicated dose-dependent binding
of '251-di- and '251-pIgA, and again very little binding of 1251-mIgA was
seen. Binding of '251-pIgA could be inhibited by increasing concentra-
tions of cold pIgA and '251-di-IgA could be inhibited by increasing
concentrations of cold di-IgA. The binding of 1251-pIgA was not
influenced by excess cold BSA, IgG or asialofetuin. Scatchard analysis
of the data revealed the presence of 2.3 x iO binding sites/cell for
di-IgA with an affinity of 1.6 x 106 M1 and 1.4 x io binding sites/cell
for pIgA with an affinity of 7.5 x 106 M. These results provide
evidence for the existence of a putative specific IgA receptor on rat
mesangial cells. Additional studies are in progress to characterize this
receptor on rat MC.
Experimental IgA nephropathy in rats induced by monoclonal poly-
meric rat IgA antibodies. R.K. Stad, J.A. Brujjn, DJ. van Gjjlswjjk-
Janssen, L.A. van Es, and M.R. Daha, Departments of Nephrology and
Pathology, University Hospital Leiden, The Netherlands. An experimen-
tal model of IgA glomemlonephritis (IgA-GN) in rats was induced by the
in Situ deposition of IgA directly into the glomerular mesangium. There-
fore, F(ab')2 anti-Thy-I monoclonal antibody (mAb) was used to anchor an
antigen DNP, (2,4- dinitrophenol), in the glomeruli of rats. Subsequent
infusion of rat polymeric (p-) or monomeric (m-) IgA monoclonal antibody
968 Abstracts
with specificity for DNP resulted in mesangial deposition of IgA in both
groups of rats. However, acute proteinuria was observed only in pIgA
treated rats and not in PBS- and mIgA treated rats. Immunofluorescent
analysis revealed deposition of C3 in an identical pattern to that of IgA
in the glomeruli of pIgA treated rats. No deposits of C4 or Clq were
seen in these animals. Rats receiving mIgA or PBS displayed no
detectable C3, C4 or Clq deposition. The amount of proteinuna in pIgA
treated rats was related to the amount of deposited C3. The presence of
intraglomerular monocytes was only observed two days after pIgA
treatment. By light microscopy, aneurysm formation, mesangial prolif-
eration and matrix expansion were seen only in pIgA treated rats.
However, by seven weeks post-injection complete resolution of the
lesions was observed. No histological nor immunopathological renal
changes were observed in PBS and mIgA treated rats. In conclusion, an
acute form of IgA-GN in rats was induced by pIgA but not by mIgA.
This reproducible model provides a basis for further study into the
mechanisms of inflammation in IgA-GN.
Selective and segmental lysis of the visceral epithelial cells (VEC) leads
to increased bulk flow through the capillary wall (CW) causing intracap-
illary thrombosis resembling the hyalinosis as seen in focal and segmental
glomerulosclerosis (FSGS). W. Laurens, B. Van Damme, P. Steels, and
1'. Vanrenterghem, Katholieke University Leuven and Limburgs Uni-
versity Centrum Diepenbeek, Belgium. In previous experiments we
have shown that segmental and selective lysis of the VEC by injecting
a minute amount of a saponin solution in Bowman's space leads to the
typical lesions of FSGS. The present experiments were designed to
analyze further the sequence of events leading to these lesions. In a new
series of experiments we injected colloidal carbon (CC) 30 mg/lOO g
body weight or 10 mg/l00 g body weight intravenously before injecting
10 nI of a saponin solution (0.6 mg/mI in 0.05% Lissamin Green in
saline) ata rate of 10 nI/mm in Bowman's space. Biopsies were taken
after seven days to be studied by light microscopy. In the injected
glomeruli a coagulum of carbon particles could be noted in some
capillaries of the glomerular tuft. This resembled the hyalinosis lesions
of FSGS. Biopsies taken after 40 minutes to be studied by transmission
electronmicroscopy (in experiments without using CC) showed selec-
tive and segmental lysis of the VEC. In some capillaries with a denuded
basement membrane a coagulum containing fibrin was seen. In view of
these results we propose that selective and segmental lysis of the VEC
leads to an increased bulk flow through the CW in this region. In some
of these capillaries the change in hemodynamics is sufficient to cause
thrombosis represented as hyalinosis. The regions of the basement
membrane denuded of VEC can come in contact with the parietal
epithelial cells leading to an adhesion. Both lesions, hyalinosis and
adhesions, are essential features of FSGS.
The development of end-stage, fibronectin containing lesions in exper-
imental glomerulosclerosis is the result of specific accumulation. E.G.
Bergijk, J.J. Baelde, E. de Heer, P.D. Killen, Ph.J. Hoedemaeker, and
J.A. Brujjn, Department of Pathology, University of Leiden, The
Netherlands, and Department of Pathology, University of Michigan,
Ann Arbor, Michigan, USA. We studied the processes leading to the
development of glomeruloscierosis in chronic graft-versus-host disease
(GvHD), a mouse model for lupus nephritis, and in chronic serum
sickness, a rat model for immune complex nephritis. In both models
glomeruloscierosis was preceded by expansion of the mesangial matrix
and thickening of the glomerular basement membrane (GBM). At this
early phase in the disease the amounts of extracellular matrix (ECM)
components, including laminin, fibronectin, and collagen types IV and
VI, increased. mRNA levels for these components increased before
morphological changes were detectable. In both experimental models
sclerotic lesions mainly consisted of fibronectin, dispersing the other
ECM components peripherally in the mesangial matrix and GBM.
Increased fibronectin could result from non-specific trapping, specific
binding of circulating fibronectin and/or local synthesis. Prior to the
onset of mesangial expansion, fibronectin mRNA levels increased only
twofold in kidney cortex and in isolated glomeruli, and these levels
were sustained throughout the development of glomerulosclerosis. In
contrast, mRNA levels for collagen type IV ol and a2, and laminin B!
and B2 increased up to eightfold. These findings suggest that increased
fibronectin in experimental glomerulosclerosis is due in large part to
local accumulation from the circulation rather than de novo synthesis.
This may not be a non-specific event as preliminary evidence suggests
that 131 integrins are upregulated in these models, and other components
from the circulation are not present in the sclerotic lesions. Indeed,
using antibodies specific for cellular fibronectin, sclerotic matrices in
chronic serum sickness did not demonstrate an increase in cellular
fibronectin. We conclude that specific accumulation, and not de novo
synthesis, of fibronectin plays a major role in the development of
experimental glomerulosclerosis.
Albuminuria in the late heterologous phase of anti-GBM nephritis in
beige mice is complement independent but leukocyte dependent. G. W.
Feith, K.J.M. Assmann, M.J,J.T. Bogman, A.P.M. van Gompel, J.
SchalkwUk, and R.A.P. Koene, Departments of Pathology, Dermatol-
ogy, and Nephrology, University of Nmegen, The Netherlands. Beige(C57BL/6J, bg/bg) mice, which are deficient for leukocytic neutral
proteinase activity, do not develop albuminuria within 24 hours after
i.v. injection of rabbit anti-mouse GBM (RaMGBM) antibodies, not-
withstanding a glomerular influx of neutrophils and necrosis compara-
ble to that in congenic control (C57BL/6J, +/+) mice. Beige mice,
however, gradually develop an albuminuria after day 1. We studied the
mediators that are responsible for the albuminuria occurring in this late
stage of the heterologous phase in beige mice. C3 depletion with CoVF
had no effect on the albuminuria (13,476 4393 vs. 10,504 3680 g/l8
hr in the control group, N = 8) or the extent of glomerular damage as
studied by light microscopy and immunofluorescence (IF) at day 3. IF
examination of kidneys on day 3 after induction of the nephritis, using
a novel panmacrophage (<Ia) mAb (FAI 1), did not reveal an increased
number of glomerular 1 (1.1 0.2 'F/glomerulus vs. 0.8 0.3 in
untreated control mice, N = 5 each). Administration of RaMGBM, after
leukocyte depletion by total body irradiation (TBI), prevented the
induction of albuminuria on day 3 (16 10 jg/l8 hr, N = 5), and the
morphological damage to the kidneys. In addition, i.v. injection of
equimolar amounts of RaMGBM IgG F(ab')2 fragments, which showed
an even larger binding to the GBM than the intact antibodies (31.8 3.3
vs. 17.3 1.9 pmoles kidney fixed antibody/kidney), did not result in
albuminuria or glomerular alterations. These findings show that the
albuminuria in the late heterologous phase (day 3) of passive anti-GBM
nephritis is independent of C and probably also of macrophages.
Fc-mediated damage by leukocytes appears to play a major role in this
phase. While intact neutral proteinase activity of neutrophils is required
for the induction of albuminuria in the early phase (day 1), this is not the
case in the late phase (day 3).
The clearance ratio of IgGl/IgG2 does not assess glomerular charge
selectivity in humans. P.C. Wever, G.C.M. Koo,nen, B.A.C. van Acker,
J. W. Groothoff, R. T. Krediet, and L. Arisz, Renal Unit, Academic
Medical Center, Amsterdam, The Netherlands. The clearance ratio of
molecules of the same size but with a different charge, for instance
anionic and cationic dextran fractions, has been used to assess glomer-
ular charge selectivity. In humans this can only be done by using
endogenous solutes, like IgG subclasses and amylase isoenzymes.
Unlike dextrans, proteins are also subject to tubular reabsorption: IgG
90%, amylase 45%. To investigate possible interference of tubular
reabsorption, we compared the clearance ratio of IgGl (p1 8.2 to 9.0) to
IgG2 (p1 6.8 to 8.0) with the clearance ratio of pancreas amylase (PA: p1
7.0) to salivary amylase (SA: p1 5.9 to 6.4) in three groups of subjects:
seven healthy volunteers (HV), five patients with minimal change
nephrotic syndrome (MCNS) and six patients in the polyuric phase of
acute tubular necrosis (ATN). These conditions were chosen, because
MCNS represents a situation with loss of glomerular charge and
essentially normal tubular function, while polyuric ATN is an example
of severely disturbed tubular function. All cationic/anionic clearance
ratios should be in excess of 1.0 if tubular reabsorption is independent
of charge.
Subjects
Cationic/anionic clearance ratios
PA/SA IgGI/IgG2
HV (N = 7) 3.2 1.0 0.5 0.1
MCNS (N = 5)
ATN (N = 6)
1.1 0.2
1.7 05a,b
0.2 o.la1.1 0.4
mean SD, aP < 0.05 compared to HV, b P < 0.05 compared to
MCNS, Mann-Whitney U-test
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The results of the PA/SA ratio (highest in HV and lowest in MCNS) are
consistent with glomerular charge selectivity, but the IgGI/1g02 ratio
was below 1.0 in all HV, while the highest value was found in the ATN
patients. These findings point to a charge selective tubular reabsorption
of IgG. Because amylase is reabsorbed to a lesser extent, the PA/SA
ratio is less disturbed. We therefore conclude that the IgGl/IgG2 ratio
cannot be used to assess glomerular charge selectivity, because of the
high interference of charge selective tubular reabsorption.
Optimalization of thalamate and hippurate clearance measurements in
patients with severe impaired renal function by adjustment of the infusion
rate according to prior estimation of GFR and ERPF with the Cockroft
formula. R. Zietse, F.H.M. Derkx, B. Pos, P.J. Blankestzjn, A.A.M.
Balk, M.A.D.H. Schalekamp, Departments of Internal Medicine I and
Cardiology, University Hospital Dijkzigt, Erasmus University, Rotter-
dam, The Netherlands. Aim of the study: Optimalization of glomerular
filtration rate (GFR) and effective renal plasma flow (ERPF) measure-
ments in patients with a wide range of GFR using '251-iothalamate and
'311-iodohippurate as clearance markers. Methods: A loading dose,
which would give a plasma concentration of 500 CPM/mI for i251
thlamate and 125 CPM/ml for '311-hippurate, was calculated assuming a
volume of distribution of 25% of the body weight. To maintain these
plasma concentrations the intravenous infusion rate of the markers was
calculated from an estimation of the GFR by using the Cockroft
formula: (GFR = {140 — age (yr)} x body weight (kg) divided by 0.815
times serum creatinine (rmolIliter) for men and 0.959 times creatinine
for women) and by assuming ERPF = 4 times GFR. The computer
program for the calculation of the loading and maintenance dose was
written in Lotus 123 format. Blood samples were collected at 90, 135
and 180 minutes after start of the infusion. Urine was collected every 45
minutes. The clearances were calculated by dividing the infusion rate or
the urinary excretion rate by the plasma concentration. Patients re-
ceived an oral water load of 300 ml prior to the infusion and 150 ml
water each hour. Patients, insulin-dependent diabetes mellitus N = 74,
nephrotic syndrome N = 18, heart transplantation N = 69, kidney
transplantation N 51. Age: 35 years (9 to 75) and serum creatinine 134
mol/liter (45—526, mean and range). Results: Constant plasma concen-
tration of the clearance markers was obtained after 90 minutes even
when the GFR was as low as 10 mI/mm. The clearances of thalamate 78
3 mI/mm (mean SE) and hippurate 347 24 based on infusion rate
were not different from the clearances based on the urinary excretion,
79 3 and 345 23, respectively. In diabetics we observed higher
intra-individual variability of GFR and ERPF results based on urinary
excretion than in the other groups. This higher variability appeared to
be related to a higher variability of urinary excretion determination in
the diabetics probably due to voiding difficulties. Such a difference
between diabetics and non-diabetics was indeed not observed when
results were calculated on the basis of infusion rate. The Cockroft
formula underestimates GFR in the diabetics by 29%. Conclusions:
GFR and RPF can be accurately measured by commonly used clear-
ance methods without urine collections, even in patients with severely
impaired renal functions. This can be done by adjustment of the
infusion rate of the clearance markers by prior estimation of GFR and
ERPF with the Cockroft formula. In diabetics GFR and ERPF should
preferably be measured using a method independent of urine collection.
Estimations of GFR in diabetics using Cockroft formula markedly
underestimates GFR.
Accuracy of GFR slope determination in long-term studies is improved
by correction for incomplete urine collection. A.J. Apperloo, D. de
Zeeuw, and P.E. de Jong, University Hospital, Groningen, The Neth-
erlands. Studies on the effect of interventions on long-term renal
function decline use GFR values calculated from plasma concentrations
and urinary excretions of GFR markers like inulin or iothalamate (jot).
However, due to inaccuracies in urine collection without bladder
catheterization, intra-patient variation of this UV/P method standard
GFR is considerable, and the accuracy of slope estimations may
therefore be hampered. In steady state conditions the clearances of
hippuran (hip) calculated by IV/P and UV/P method have been proven
to be interchangeable in case of perfect urine collection. Thus, standard
GFR can be corrected by using the IV/P and UV/P clearances of
simultaneously infused '311-hippuran as an ERPF marker, by the
formula:
C — hip (IV/P)Corrected C — jot = ____________ - C — iot (UV/P)C — hip (UV/P)
We studied whether the accuracy of slope determinations could thus be
improved in a prospective study in 61 patients with renal disease and a
baseline GFR 60 3.1 mI/mm. Renal function was calculated by
standard C-iot and corrected C-jot every 24 weeks. Slopes were
calculated from at least four measurements (range 4 to 7) and mean
follow-up was 103 weeks, range 60 to 132 weeks.
Mean values SEM Corrected GFR Standard GFR
Individual SE of GFR 3.46 0.24 5.01 0.61 P < 0.01
mi/mm (range) (0.81—11.92) (0.89—28.21)
Slope —2.81 0.44 —1.85 0.66 P = 0.064
mi/mm/yr (range) (—15.81—4.22) (—27.53—11.36)
Error of slope 2.07 0.17 3.16 0.37 P < 0.008
mI/mm/yr (range) (0.44—6.48) (0.49—12.43)
We conclude that the accuracy of GFR measurements is improved
using the corrected iothalamate clearance. Taking into account that,
GFR decline in most studies is about 3 mI/mm/yr on the average, a
possible difference between two treatment modalities may thus be
detected more rapidly.
The effect of increased intraperitoneal pressure on fluid and protein
transport during CAPD. A.L.T. Imholz, G.C.M. Koomen, D.G. Strutjk,
L. Arisz, and R.T. Krediet, Renal Unit, Academic Medical Center,
Amsterdam, The Netherlands. A decline in water removal during
CAPD can be caused by increased lymphatic absorption rate (LAR)
and/or decreased transcapillary ultrafiltration rate (TCUFR). Because
intraperitoneal pressure (IPP) can influence both, we studied the effect
of increased IPP on fluid kinetics. Protein (Pr) clearances (C) were
determined of i32-microglobulin (f32M), albumin (A), transferrin (T), IgG
and a2-macroglobulin (a2M). Two peritoneal permeability tests (2 X 2
hrs, glucose 1.36% dialysate, dextran 70 as volume marker) were
performed in six CAPD patients in supine position. IPP was increased
in either the first or the second test by means of a tightening girdle with
inflatable cuffs. IPP was higher: 20.7 1.2 mm Hg with (HIPP) and
lower: 9.7 0.6 without (LLPP) girdle (P < 0.001). Net water removal
was lower during HIPP. This was caused by a higher LAR (mI/mm):
1.66 0.28 vs. 0.98 0.22 (P < 0.05) and a lower TCUFR (mI/mm):
1.64 0.30 vs. 2.03 0.28 (P = 0.06). A fall in C was found during
HIPP: /32M —13%, A —15%, T —28%, IgG —35%, a2M —35%.
According to Starling's law, the fall in TCUFR during HIPP can only be
caused by a decrease in hydrostatic pressure gradient (PG) between
peritoneal capillaries and abdominal cavity andlor a decline in effective
peritoneal surface area (EPSA), since osmotic PG was similar in both
tests. TCUFR decreased 19%, whereas EPSA, represented by the mass
transfer area coefficient of creatinine (mi/mm), decreased 11% (12.8
1.6 vs. 11.4 1.4, P < 0.05). Therefore, the remaining 8% was probably
caused by a fall in hydrostatic PG. When convection would be the main
mechanism for the transport of Pr, the fall of all C would be similar.
However, the fall in C was more pronounced the higher the molecular
weight. Consequently, the restriction coefficient (that is the slope of the
power relationship between Cp and free diffusion coefficient Pr) was
higher during HIPP (2.16 0.08) than during LIPP (1.97 0.06, P <
0.05). This also implies that the intrinsic peritoneal permeability is
decreased during HIPP, probably caused by a decrease in large pore
size. It is concluded that HIPP increases LAR, and decreases TCUFR
and solute transport. The latter is caused by a lower EPSA and intrinsic
permeability.
Non-invasive measurement of blood volume and extracellular fluid
volume during haemodialysis. J.P.P.M. de Vries, P.M. Kouw, B.J.M.
van der Meer, P.L. Oe, A.J.M. Donker, and P.M.J.M. de Vries,
Department of Nephrology, Free University Hospital, Amsterdam, The
Netherlands. Hypovolemia-induced hypotension is a serious problem
in hemodialysis therapy. During hemodialysis the intravascular com-
partment will shrink due to ultrafiltration. Although refill from the
interstitium will compensate this shrinkage partly, blood volume (BV)
decrease can amount up to 20% of the startinu value. The refill canieitv
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of the interstitium depends on the extracellular fluid volume (EFV).
Based on a non-invasive conductivity measurement of EFV at the end
of the previous dialysis session, a group of 37 hemodialysis patients was
divided in three groups: eight overhydrated (0), 11 underhydrated (U)
and 18 normohydrated (N) patients. Using an on-line optical reflection
method BV decrease was continuously measured. BV decrease in
group U (15.0 5.7%) was significantly higher than in group N (10.3
5.8%, P < 0.025). For group 0(8.0 5.3%) it was lower than in N (NS).
BV decrease calculated for liter ultrafiltration was: 3.3 1.5 (N), 4.4
1.5 (U; U vs. N, P < 0.05) and 2.7 1.9%/liter (0; 0 vs. U, P < 0.025;
o vs. N, NS). The percentage sessions with hypotension was: 20.5
23.5% (N), 48.5 20.2% (U; U vs. N, P < 0.005) and 6.5 6.5% (0;
o vs. N, NS), The mean total BV decrease at the start of seven
hypotensive episodes amounted 12.8 3.0% compared to 5.4 5.7% in
a group of 19 controls at the comparable point of time. BY decrease
corrected for UF-rate during the 15 minutes preceding hypotension was
significantly higher than in the control group at the same moment (6.69
3.67 vs. 2.58 3.72%/hour (P < 0,025)). It can be concluded that the
combination of on-line non-invasive measurement of BY together with
conductivity measurement of EFY gives insight in the occurrence of
hypotension, which can be used to prevent hypovolemia-induced
hypotension.
Acute potassium loading attenuates tubuloglomerular feedback (TGF)
responsiveness In rats. B. Braam and H.A. Koomans, University Hos-
pital Utrecht, Department of Nephrology, Utrecht, The Netherlands.
Stable or increased GFR coincides with a reduction in reabsorption
proximal to the macula densa during acute K-loading. Apparently, the
expected TGF-mediated decrease in GFR in response to increased
distal delivery does not occur. Therefore, the present study evaluated
the hypothesis that TGF responsiveness is diminished during acute
increases in plasma potassium concentration ([K]1). Pentobarbital-
anesthetized Sprague-Dawley rats were prepared for micropuncture.
After a 60 minute control period, in which all rats received 150 mM
NaCI at a rate of 20 LImin, 300 mri NaCl, KNO3, KHCO3 or KC1 (N
= 6 in each group) was infused at the same rate. The control infusion
was maintained in a time control group (TC, N = 6). Stop flow pressure
(SFP) responses to step increases in late proximal perfusion rate (PR)
were evaluated during the control hour and 45 to 90 minutes after
switching the infusion. [K]1 increased with 0.7 0.3*, 1.1 0.2* and
1.6 0.2* mmol/liter 90 minutes after starting the KNO3, KHCO3 and
KCI infusions, respectively, and was stable in the TC and NaCl group.
Control maximum SFP responses were 11.3 1.6 and 11.5 0.9 mm
11gm theTC andNaClgroup, and 11.8 0.8, 12.1 1.2 and 13.0 1.3
mm Hg in the KNO3, KHCO3 and KC1 group, respectively. Zero flow
SFP (SFP0) did not differ significantly between groups during the
control period. SFPO and SFP responses during the experimental period
are shown below (*P < 0.05 vs. NaCI and TC; ANOVA):
SFPO LSFP (mm Hg SE) to increases in PR
PRnI/ 0 10 15
mm
TC 43.7 1.5 —0.3 0.3 —2.4 0.7
NaC1 48.6 0.9 —0.4 0.2 —1.7 0.4
KNO3 46.9 2.5 —0.1 0.1 —1.6 0.5
KHCO3 44.0 1.6 —0.0 0.0 —0.7 0.2
KCI 46.1 1.5 —0.1 0.1 —1.0 0.4
LSFP (mm Hg SE) to increases in PR
20 30 40
—6.9 0.7 —10.7 1.4 —11.1 1.5
—5.4 1.2 —10.8 1.7 —10.9 1.7
—4.1 0.8 —6.6 0.6* 7.9 0.9
—3.0 1.4 —5.0 1.4* —6.8 1.7*
—2.6 0.6 —5.8 0.7* 7.3 1.0'
No correlation between plasma [K]1 and maximum TGF response
could be demonstrated. The current data show attenuation of TGF
responsiveness during acute potassium loading in rats, independent of
the plasma potassium concentration or the accompanying anion.
Functional localization of the vascular dysfunction in cyclosporine (Cs)
toxicity. M. Verbeke, J. Van De Voorde, D. Kesteloot, L. De Ridder,
and N. Lameire, University Ghent, Pasteurlaan, Gent, Belgium. Pre-
vious experiments have shown that the vasodilatory response to
Acetylcholine (Acechol) (endothelium dependent) and nitroglycerine(endothelium independent) was suppressed in Cs-treated rats. The
present experiments are an attempt to further characterize the vascular
toxic effects of Cs. Male Wistar rats (280 to 330 g) received either Cs (20
mg/kg, N = 7) or vehicle (Y, N = 7), orally for 10 days. In a first group
of in vivo experiments, L-NAME, a NO synthase inhibitor was given in
a dose of 1 mg/kg. In Cs-rats, renal blood flow (RBF) decreased from
3.92 0.72 mI/mm to 2.0 0.58 mI/mm (P <0.001; delta: —49%), while
blood pressure (BP) rose from 106 8.4mm Hg to 143.3 10.7mm Hg
(P < 0.001; delta: +35%). In control rats, RBF decreased and BP
increased with only 17% and 18%, respectively. In vitro, isolated aortic
rings of both experimental groups (N = 6) were preconstricted with a
dose of iO M norepinephrine, and L-NAME (10 M) was subsequen-
tially added. An additional vasoconstriction (YC) was observed that
was not significantly different between both experimental groups.
However, the cGMP content of the aortic rings after stimulation with
Acechol was remarkably suppressed in the Cs-treated rats (22.7 in CS
vs. 333.67 117 pmol/mg protein in control rats). In conclusion, the
systemic and renal circulation in Cs-treated animals is in vivo signifi-
cantly more sensitive to NO blockade compared to control rats. Since
the in vitro VC after L-NAME is not different in Cs vs. control vessels,
but the cGMP production by the vascular smooth muscle cells (YSMC)
is suppressed, the previously found blunted VD to Acechol in aorta's
from Cs treated animals can be explained predominantly by a YSMC,
rather than by an endothelial cell dysfunction.
Natural history of idiopathic IgA nephropathy and thin basement
membrane (GBM) disease in adults. C. Nieuwhof, W. Grave, C. Dooren-
bos, K. Leunissen, E. Zeppenfeldt, and P. van Breda Vriesman,
Regional Working Party on Kidney Diseases, Limburg, The Nether-
lands. Patients were derived from a prospective regional epidemiolog-
ical study carried out from 1978—1984 and described elsewhere. Briefly,
renal biopsies were taken from adults with persisting erythrocyturia or
recurrent hematuria of at least 0.5 years duration but within two years
of patient identification and of unknown origin. Follow-up was 11.0
years median, range 8 to 13 years. For the purpose of this study patients
were divided into three subsets on the basis of proteinuria and serum
creatinine (Sr) concentration measured at the time of renal biopsy. The
first subset (N = 15) consisted of non-proteinuric (24 hr proteinuria < 1
g), normotensive and non-azotemic patients with IgA nephropathy;
they were compared to non-proteinuric, normotensive and non-
azotemic patients with thin GBM disease (N = 16) and erythrocyturic
patients with normal renal tissue (N = 23). Groups were of comparable
median age. Of the patients with IgA nephropathy, six developed
non-familial hypotension, associated with an increase of proteinuria in
one; none developed azotemia. Of the patients with thin GBM, eight
developed non-familial hypertension, associated with an increase in
proteinuria in five. Of the normal controls, two developed non-familial
hypertension without an increase in proteinuria. The second subset of
patients with IgA nephropathy (N = 12) had proteinuria> 1.0 but less
than < 3.0 g. At the end of follow-up two showed mild azotemia, one
was on dialysis six years after renal biopsy, and three showed hyper-
tension associated with an increase in proteinuria in one. The third
subset of patients with IgA nephropathy (N = 2) had mild azotemia (Sr
> 120 smol/liter < 160 mol/liter) at the time of renal biopsy. Both
developed renal insufficiency, necessitating dialysis within five years of
follow-up. This long-term follow-up study shows thin GBM disease and
non-proteinuric IgA nephropathy to be comparable in terms of the risk
for developing proteinuric (presumably renal) hypertension; this risk
significantly exceeded (P < 0.05; Fisher's test) that of erythrocyturic
controls. For the non-azotemic normotensive patients with igA ne-
phropathy, only the severity of proteinuria was associated with in-
creased risk for developing renal insufficiency, but this was of no
prognostic significance for the individual patient.
Interleukin la (IL-la) enhances the production of interleukin 6 (IL-6)
by human proximal tubular epithelial cells (PTEC) in vitro. BA. Yard,
R.N. Boswell, E. Schrama, L.A. van Es, M.R. Daha, and F.J. van der
Woude, Department of Nephrology, University Hospital Leiden, The
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Netherlands. In a previous study we reported on the production of
TNFa by cultured human PTEC in vitro. Not only TNFa but also IL-6
has been shown to be implicated in various renal disorders, including
renal allograft rejection. During transplant rejection high levels of IL-6
may be found in the urine. It is not clear at present whether this IL-6 is
derived directly from the circulation or if it may have been produced in
the kidney. We have investigated whether PTEC in vitro are able to
produce IL-6 and whether inflammatory cytokines are able to regulate
IL-6 production. To this end we cultured 10 PTEC lines, and superna-
tants were tested for the presence of IL-6 using the IL-6 dependent B9
cell line. A heterogenous production was observed between the cell
lines ranging from 430 to 9209 U/m11105 cells/24 hrs. In all lines
introduction of IL-la upregulated IL-6 production in a dose and time
dependent fashion. Maximal production was achieved using a concen-
tration of I ng/ml after 48 hours of stimulation (30000 U/ml/105 cells).
Other cytokines did not influence IL-6 production. Production of IL-6
was constant over a period more than two months in which the cells had
been passaged five times. However, the ability of PTEC to respond to
IL-la was decreased already after the second passage. Production of
!L-6 by PTEC was de novo since cycloheximide reversibly blocked
IL-6 production. The molecular weight of IL-6 produced by PTEC
ranged between 26 to 28 kd, similar to r!L-6. Using PCR analysis we
could show an increase in mRNA for IL-6 upon IL-la stimulation,
suggesting that regulation of IL-6 production was at the transcriptional
level. In summary this study provides evidence that IL-la at concen-
trations well within the range attainable in vivo, has the ability to induce
human PTEC in vitro to synthesize and secrete IL-6. Production of IL-6
by PTEC may be an important mechanism by which local and systemic
inflammatory processes are regulated.
Point mutations in the vasopressin type 2 receptor gene (AVPR2) are
associated with nephrogenic diabetes insipidus. N. Knoers, A. v.d,
Ouweland, J. Dreesen, M. Verd,Jk, L.A.H. Monnens, andB.A. v. Oosi,
Departments of Human Genetics and Pediatrics, University Hospital
Nijmegen, Nmegen, The Netherlands. Nephrogenic diabetes insipidus
(ND!) is mostly an X-linked recessive disease, characterized by poly-
uria, polydipsia, fever, periods of life-threatening dehydration, and
failure to thrive. These clinical features are attributed to an intrinsic
defect in the distal renal tubule, which results in a failure of end-organ
response to either endogenous or exogenous arginine vasopressin.
Untreated, the disease may lead to mental retardation, which can run
the gamut from mild memory deficits to severe retardation. By genetic
linkage analysis the ND! gene has been shown to reside in the
subterminal region of the X chromosome long arm, in band Xq28.
Although the pathogenesis of ND! was not exactly known, the adeny-
late cyclase-bound vasopressin type 2 receptor has been considered as
the possible site of the underlying defect. This assumption was sup-
ported by the discovery of functional vasopressin V2 receptor activity
in somatic cell hybrids that carried at least the human Xqter region.
Very recently, the human and rat cDNA for the vasopressin V2
receptor (AVPR2) have been identified, which enabled us to test the
hypothesis whether certain alleles of the AVPR2 gene are the underly-
ing cause of ND!. Using a panel of somatic cell hybrids, we have
mapped the AVPR2 gene close to the color vision genes in Xq28. This
location is entirely compatible with the genetic map location of NDI.
We have tested eight X-linked ND! probands and their families for
mutations in the most conserved region of the AVPR2 gene. In three of
them we have found point mutations giving rise to non-conservative
amino acid substitutions. Cosegregation of the mutated AVPR2 gene
with ND! was observed in all families. The finding of mutations in the
AVPR2 gene is the direct evidence that the V2 receptor gene is identical
with the ND! gene. Direct mutation analysis is now applicable for
accurate carrier detection and early (prenatal) diagnosis of ND!.
Preferential occurrence of anti-lactoferrin antibodies in sera of patients
with rheumatoid vasculitis. I.E.M. Coremans, E.C. Hagen, M.R. Daha,
F.J. van der Woude, E.A.M. van der Voort, C. Kleijburg-van der Keur,
and F.C. Breedveld, Departments of Rheumatology and Nephrology,
University Hospital, Leiden, The Netherlands. Anti-neutrophil cyto-
plasmic antibodies (ANCA) have been described in patients with
nephritis and/or vasculitis, particularly Wegener's granulomatosis.
ANCA are directed against cytoplasmic enzymes such as proteinase-3
(PR-3), myeloperoxidase (MPO), neutrophil elastase (NE) and lactof-
errin (LF). ANCA have been reported in patients with rheumatoid
arthritis (RA) and an association with vasculitis has been suggested. In
this study the presence of ANCA was investigated in sera from patients
with RA complicated by vasculitis (RV), uncomplicated RA and healthy
controls (HC). ANCA were found in 43% of the 49 sera of patients with
RV, in 36% of sera of 50 RA patients, and 4% of the 50 HC sera. Further
characterization of the ANCA reactivity revealed a high frequency of
anti-LF antibodies (Ab) in sera of RV patients (45%), as compared to
RA patients (4%) and HC (2%). Reactivity to the other cytoplasmic
antigens tested (PR-3, MPO, NE) did not differ significantly between
these groups. The reactivity of the RV sera with LF was established
using various techniqjes, such as fluid-phase inhibition with purified
LF, immunoprecipitation with '251-LF, and Western blots. The anti-
body reactivity resided in IgG and was located in the F(ab')2 fragments.
The mechanism by which anti-lactoferrin antibodies contribute to
vasculitis remains to be elucidated.
A cANCA antigen of Wegener's disease, proteinase 3, enhances classi-
cal pathway complement activation. R. Wes Leid, I. van der He,jden,
B.E.P.B. Ballieux, C. van der Keur, J.E. Schouten, E.G. Hagen, L.A.
van Es, F.J. van der Woude, and M.R. Daha, Department of Nephrol-
ogy, University Hospital Leiden, The Netherlands. Antibodies against
the cANCA antigen, proteinase 3, have been shown to be associated
with Wegener's disease. We have purified this enzyme to homogeneity
by sequential chromatographic procedures, The purified enzyme dis-
plays the characteristic triplet on 10% SDS-PAGE and has 1,170
milliunits of enzymatic activity per mg of protein. Activation of
neutrophils in vivo results in both release of neutrophil elastase and
proteinase 3. Furthermore, neutrophil elastase has been shown to
cleave and inactivate the major plasma inhibitor of classical comple-
ment pathway activation, Cl-inhibitor. Therefore, we have determined
whether proteinase 3 could influence complement activation. Incuba-
tion of highly purified human Cl-inhibitor with equally pure human
leukocyte proteinase 3, resulted in a dose- and time-dependent inacti-
vation of Cl-inhibitor hemolytic activity. This inactivation was accom-
panied by proteinase 3 dependent cleavage of the Cl-inhibitor into an
83,000 Kd fragment. The formation of the 83,000 Kd fragment followed
a time course which was identical with inactivation of hemolytic
activity. Within 30 minutes more than 90% of the hemolytic activity was
lost. This inactivation was selective, as human Clq was not degraded in
a similar time period. Moreover, when 100 g of IgG isolated from each
of six Wegener's granulomatosis patients with cANCA titers to pro-
teinase 3 was incubated with 3 mU of proteinase 3, little to no cleavage
of Cl-inhibitor was observed. In contrast, 100 g of IgG from normal
donors was ineffective in affording protection to Cl-inhibitor incubated
with proteinase 3. For the first time, we have shown a relationship
between the release of proteinase 3 and its possible role in amplification
of complement-dependent inflammation. These results may be of im-
portance in our understanding the pathogenesis of Wegener's disease.
A prospective clinical trial comparing low dose OKT3 prophylaxis and
prednisolone cyclosporine treatment in renal transplant recipients.
Karine J. Parlevliet, Ineke J.M. ten Berge, Joep M. Wilmink, Janto
Surachno, and Peter Th.A. Schellekens, Renal Transplant Unit, De-
partment of Internal Medicine, Academic Medical Center, University
of Amsterdam, Amsterdam, The Netherlands. !n a prospective clinical
study we tested immunosuppressive properties and toxicity of low dose
OKT3 induction therapy in renal transplant recipients. Fifty consecu-
tive renal transplant recipients were alternately assigned to low dose
OKT3 induction (that is 0.5 mg OKT3 twice daily for 10 days in
conjunction with prednisolone/azathioprine) or conventional treatment
consisting of prednisolone/cyclosporine. The two groups were compa-
rable with respect to age, sex, HLA matching, immunization and cause
of renal disease. At 6 to 20 months follow-up low dose OKT3 induction
significantly reduced the incidence of acute rejections compared to
prednisolone/cyclosporine (21% vs. 52%, P = 0.02). All rejections
occurred in the first six weeks after transplantation and the mean day of
onset of rejection was similar in the two groups. There was a trend
towards an improved graft function after low dose OKT3 induction
(creatinine clearance at six months follow-up being 62 ml/min vs. 51
mi/mm in the prednisolone/cyclosporine group) although no significance
was reached (P = 0.08). Patient and graft survival in the OKT3 and the
prednisolone/cyclosporine group were similar (92% vs. 96% and 92%
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vs. 84%). The same holds true for the incidence and duration of delayed
graft function and the occurrence of major infectious complications
such as sepsis or CMV disease. Furthermore, compared to a historical
control group treated with 5 mg OKT3 daily for acute rejection, low
dose OKT3 induction therapy appeared to cause less side effects. Low
dose OKT3 resulted in a rapid depletion of CD3+ cells. During the
second half of the course weak CD3+ cells reappeared. OKT3 trough
levels during low dose OKT3 averaged 80 ng/ml. Only 25% of low dose
OKT3 treated patients developed antibodies to OKT3. We conclude
that low dose OKT3 induction therapy is superior to prednisolone/
cyclosporine in preventing acute rejection after renal transplantation
and is better tolerated than conventional OKT3 treatment.
Mathematical modeling of the '23t-hippuran renogram, a new tech-
nique for non-invasive measurement of intrarenal blood flow distribution.
W.M.T. Janssen, D. de Zeeuw, H. Beekhuis, R. de Bruin, and P.E. de
Jong, Departments of Nephrology and Nuclear Medicine and The
Computer Center, University of Groningen, The Netherlands. Labeled
microsphere injection is the standard technique for measuring renal
cortical and medullary blood flow distribution. The drawback of this
method is its invasive character necessitating renal extirpation. To
overcome this drawback we designed a new non-invasive method based
on hippuran-renography. In short, with the aid of a y-camera radioac-
tivity time curves were obtained of regions of interest over the heart,
the outer zone and inner zone of the kidney, a designated background
area, and the bladder. The outer zone of the kidney is assumed to
represent a percentage of the cortical flow, whereas the inner zone
represents the remainder of this cortical function plus the medullary
flow. Computer-assisted mathematical analysis fitted typical analytical
functions for these time curves (constrained non-linear least square
method), using the heart function as input and the bladder function as
output. This renders the cortical and medullary contribution to the total
kidney function curve corrected for background. The method was
validated and compared to the standard microsphere technique in 10
mongrel dogs. Each dog was anesthetized with pentobarbital (6 to 12
mg/kg/hr) and received a constant infusion of dextrose (12 to 14
mi/kg/br). After equilibration of urine flow, 40 mBq of '231-hippuran was
injected (i.v.) and y-camera images were recorded for 15 to 20 minutes
in 10 second time frames. This was followed by intracardial injection of
11.3 0.1 m radiolabeied microspheres. Both procedures were
repeated after two hours, this time with differently labeled micro-
spheres, during infusion of angiotensin-I (A-I; 20 tg/min; N = 5), and
atrial natriuretic factor (ANF; 0.3 g/min/kg; N = 5). Subsequently, the
kidneys were extirpated for microsphere content analysis. Baseline
medullary flow distribution was 10.8 0.5% measured with micro-
spheres (MS), and 12.6 0.8% with the renogram method (RM). As
expected, A-! caused a fall in medullary flow by 41.7 9.6% (MS) and
by 31.8 8.0% (RM). Interestingly, ANF induced a rise in medullary
flow by 9.3 2.8% (MS) and 19.5 18.7% (RM). The changes in
medullary flow as measured by both methods correlated significantly (N
= 10; r = 0.69). We conclude that the proposed new renogram method
can be used to measure (changes in) intrarenal blood flow distribution,
and because of its non-invasive character the method may be useful in
human studies.
The role of the renal nerves in the response to head-out water
immersion (HO!). A.J. Rabelink, C.A. van Tilborg, R.J. Hene, and
H.A. Koomans, Department of Nephrology, University Hospital
Utrecht, The Netherlands. The natriuretic response to stimulation of
cardiopulmonary receptors by HO! is thought to be mediated by
suppression of renal nerve activity. Indeed, renal denervation pre-
vented the natriuresis of HO! in dogs. However, renal denervation
could not prevent the natriuresis of postural changes in monkeys,
suggesting a difference in volume control between bipeds and quadru-
peds. A recent study in renal transplant patients (NTX, denervated
kidney) also showed a normal natriuretic response to HOl. However,
this study was confounded by reinnervation of the transplanted kid-
neys, since it was carried out at an average of 6.7 years after transplan-
tation. To evaluate the role of the renal nerves in volume control in
humans, we studied the response to HO! in eight NTX within two
months after transplantation, and in eight control subjects (CON). Each
subject underwent two clearance studies: a three hour immersion study
and a time control study. All NTX were studied within two months after
transplantation to prevent the influence of renal reinnervation. Three
NTX received azathioprine and steroids. The others received cyclospo-
rin and steroids. Immunosuppression was discontinued on the study
days. GFR in the NTX was 62 7 mI/mm, and there were no episodes
of rejection. Excretory response: Sodium excretion rose from 120 21
to 204 37 .smol/min during HOl in NTX (time control: 125 18 to 112
12 tmol/min), whereas potassium excretion did not change. This
natriuresis was similar to that in CON: 105 9 to 191 19 mol/nun
during HO! and 99 16 to 94 25 during time control. Potassium
excretion did not change in CON. In both NTX and CON the natriuresis
was associated with an increase in fractional excretion of lithium: 36.8
3.0 to 41.3 3.2% and 29.9 1.4 to 34.6 0.9%. Vasomotor
response: Contrary to CON, where renal plasma flow increased during
HOI (615 39 to 674 31 ml/min, P < 0.05), there was no change in
renal plasma flow in NTX (286 41 to 288 33 ml/min). !n both groups
blood pressure fell by 10mm Hg, without any change in heart rate. GFR
did not change. Endocrine response: Baseline levels of aldosterone and
renin were comparable between the two groups. Plasma ANP was
higher in the NTX (6.7 1.1 vs. 24.9 6.9). !n both CON and NTX
plasma ANP doubled and aldosterone decreased. However, plasma
renin was suppressed during HO! in CON but not in NTX. !n conclu-
sion, NTX demonstrate a normal excretory response to HO!, although
renal vasodilatation and renin suppression is impaired. These data
suggest that the natriuresis of HO! in humans is not critically dependent
upon the presence of renal nerves.
